ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO0657

Autoantigen-Specific B Cells in Myeloperoxidase (MPO)-ANCA-Associated Vasculitis

Session Information

Category: Glomerular Diseases

  • 1401 Glomerular Diseases: Mechanisms, including Podocyte Biology

Authors

  • Chen, Dhruti P., The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
  • Moon, Young-Hyun, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
  • Gomez-Martinez, Ismael, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
  • Woodcock, Mark G, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
  • Taylor, Justin J., University of Virginia, Charlottesville, Virginia, United States
  • Falk, Ronald, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
  • Bunch, Donna O., The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Background

Therapies targeting B cells are effective in ANCA vasculitis. Autoantigen-specific ANCA producing B cells are a small but key subset though correlation with clinical activity is unknown. We hypothesize that these cells are present in active disease and repopulate in long term remission off therapy (LTROT) but other protective mediators maintain LTROT. We examined B regulatory cells in LTROT and B cell receptor (BCR) profiles of autoantigen-specific B cells.

Methods

Cryopreserved peripheral blood mononuclear cells (PMBCs) were immunophenotyped via flow cytometry. We identified autoantigen-specific B cells with biotinylated autoantigens or highly specific fluorescent tetramers loaded with MPO. Empty tetramer backbone was used to exclude non-specifically binding cells. PBMCs incubated with tetramers and enriched for fluorophore-binding cells were sorted for tetramer positive anti-MPO B cells (Tpos). Controls included MPO-tetramer negative cells (Tneg) and B cells recovered from residual fluorophore-negative cells (Aneg). Cells were expanded in vitro with antigen stimulation prior to RNA isolation for bulk BCR sequencing. MPO-ANCA in supernatant was tested by ELISA.

Results

We found increased B regulatory cell population in LTROT compared to active disease (Fig 1A). Autoantigen specific B cells are present in active disease and LTROT (Fig 1B). Patient anti-MPO B cells, but not from healthy controls, secrete anti-MPO IgG (Fig 2). Bulk BCR sequencing shows clonally expanded MPO-specific B cells and overlap in the complementarity determining region, CDR3 (higher Morosita-Horn overlap index) among patients only.

Conclusion

ANCA patients in LTROT have more B regulatory cells and repopulation of autoantigen specific B cells. Bulk BCR sequencing of anti MPO B cells from patients suggests CDR3 overlap. Single cell studies will provide data on detailed immunophenotypes and BCR clones in LTROT vs active disease.

Funding

  • NIDDK Support

Digital Object Identifier (DOI)